Oura targets $15.62 billion valuation in US IPO, roadshow launches Monday
Oura, the Finnish smart ring maker, launched its IPO roadshow on September 21, 2026, targeting a fully diluted valuation of $15.62 billion. The company and existing investors plan to raise up to $2.2 billion by selling 50 million shares priced between $40 and $44 each. Oura will list on the Nasdaq under the ticker "OURA." Eli Lilly and Dragoneer have indicated interest in purchasing up to $100 million and $300 million in shares, respectively. The company reported $1.21 billion in revenue for the nine months ended June 30, a 74% year-over-year increase.
Reference imageEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Common ground
- Oura is a real company with a real product and a defensible niche in sleep tracking, not a fraud like Theranos.
- The 73% secondary share structure in the IPO is a major red flag, signaling insiders are cashing out rather than betting on long-term growth.
- The $15.6 billion valuation is too high for a company that's still losing money and needs 10 million subscribers just to break even.
- The lockup expiration will be a key test of whether the stock price can hold without insider support.
- Apple is a serious long-term competitive threat, even if it's 3-5 years away from releasing a ring.
Points of contention
- Western Agent sees the class-action lawsuit as a fundamental trust issue that could crack Oura's entire narrative, while Neutral Agent views it as a minor marketing dispute that will settle cheaply.
- Western Agent compares Oura's regulatory risk to Theranos, but Neutral Agent says that's lazy because Oura has working products and FDA clearances.
- Neutral Agent believes Oura's 74% revenue growth is accelerating and healthy, while Western Agent argues it's unsustainable because the company burns $0.76 for every dollar earned.
- Western Agent thinks the B2B channel is just a small pilot program, but Neutral Agent sees it as a potential growth engine with near-zero customer acquisition costs.
Blind spots
- Both sides overlooked how Oura's subscription revenue stickiness at $5.99/month could provide a stable base even if growth slows.
- Neither fully explored the risk that Apple might acquire Oura instead of competing with a ring, which would change the entire investment thesis.
- The debate didn't address how rising interest rates or a broader market downturn could crush the IPO's valuation regardless of Oura's fundamentals.
WorldAttention’s read
Oura is a legitimate business with a real product and a defensible niche in sleep tracking, but its $15.6 billion IPO is overpriced and structured as an insider exit, not a growth story. The 73% secondary share offering is the clearest warning sign: the people who know the company best are selling. While the class-action lawsuit is unlikely to kill the company, it adds risk to a narrative already stretched thin by heavy losses and a long road to profitability. The lockup expiration will be the real test of value. For now, this is a well-executed liquidity event for early investors, not a safe bet for retail buyers.
Reporting timeline
Oura Smart Ring IPO Roadshow Launches, Targets $2.2 Billion Valuation
Oura launched its initial public offering roadshow on Monday, September 21, 2026, aiming to raise up to $2.2 billion by selling 50 million shares priced between $40 and $44 each. The company will list on the Nasdaq Global Select Market under the ticker 'OURA,' with trading expected to begin next week. Of the 50 million shares, Oura is offering 13.5 million and existing stockholders are selling 36.5 million; Oura will not receive proceeds from the latter. Underwriters have a 30-day option to purchase up to 7.5 million additional shares. The offering targets a fully diluted valuation of $15.62 billion, according to Reuters. Eli Lilly has signaled it may buy up to $100 million worth of shares, and investment firm Dragoneer has expressed interest in acquiring up to $300 million. Lead underwriters are Goldman Sachs, Morgan Stanley, and J.P. Morgan. Oura moved 3.6 million rings in the year through June 30, with revenue hitting $1.21 billion for the nine months ended on that date, a roughly 74% jump year-over-year. By fiscal 2026 end, the company projects its paid membership base will reach approximately 5.7 million, nearly doubling from the prior year. The IPO follows a $900 million late-stage funding round last October that valued Oura at $11 billion. Founded in 2013 in Finland, Oura is now headquartered in San Francisco. The company faces a proposed class-action lawsuit filed in August alleging its ring cannot measure sleep stages with the accuracy claimed in marketing; Oura disputes the allegations. The IPO arrives amid market fragility due to AI trade turbulence, climbing bond yields, and uncertainty over Federal Reserve interest rate policy.
Read sourceOura smart ring IPO roadshow launches, targets $2.2 billion valuation
Oura launched its initial public offering on Monday, aiming to raise up to $2.2 billion by selling 50 million shares at a price range of $40 to $44 each. The company has applied to list on the Nasdaq Global Select Market under the ticker symbol 'OURA,' with trading expected to begin next week. Of the 50 million shares, Oura is offering 13.5 million and existing stockholders are offering the remaining 36.5 million; Oura will not receive proceeds from the shares sold by existing stockholders. The offering targets a fully diluted valuation of $15.62 billion. Eli Lilly has signaled it may buy up to $100 million worth of shares, and investment firm Dragoneer has expressed interest in acquiring up to $300 million worth. Lead underwriters are Goldman Sachs, Morgan Stanley, and J.P. Morgan. According to its IPO prospectus, Oura moved 3.6 million rings in the year through June 30, with revenue hitting $1.21 billion for the nine months ended on that date, a roughly 74% jump from the same period a year earlier. The IPO comes after a late-stage funding round last October brought in $900 million and pushed its valuation to $11 billion. Oura is also contending with a proposed class-action lawsuit filed in August alleging its ring cannot measure sleep stages with the accuracy claimed in marketing; Oura disputes the allegations. The IPO arrives at a fragile moment for markets amid AI trade turbulence, climbing bond yields, and uncertainty about Federal Reserve interest rate policy.
Read sourceSmart Ring Maker Oura and Investors Plan U.S. IPO of Up to $2.2 Billion
Oura, a Finnish health-focused smart ring manufacturer, along with some of its investors, has filed for an initial public offering (IPO) in the United States, aiming to raise up to $2.2 billion. According to a filing with the U.S. Securities and Exchange Commission on Monday, the company plans to offer 50 million shares at a price range of $40 to $44 per share. The offering consists of 13.5 million shares from the company and 36.5 million shares from existing shareholders. At the top of the price range, the company's market capitalization would be approximately $14.1 billion. This follows a $875 million Series E funding round in 2025 that valued the company at around $11 billion. For the nine months ending June 30, Oura reported revenue of $1.21 billion but a net loss attributable to shareholders of $924.3 million, which includes deemed dividend payments to certain preferred shareholders. The company has sold approximately 3.6 million rings in the past year and has over 5 million paid subscribers. Goldman Sachs, Morgan Stanley, JPMorgan, Allen & Co, and Jefferies are the lead underwriters for the IPO, which is expected to list on the Nasdaq under the ticker symbol 'OURA'.
Read sourceShow 2 older updatesHide older updates
Oura targets $15.62 billion valuation in US IPO, testing fall listing appetite
Smart ring maker Oura is targeting a fully diluted valuation of $15.62 billion in its US initial public offering, as it kicked off its roadshow on Monday. The deal comes amid uncertainty around the AI trade, rising bond yields, and Federal Reserve rate hikes that have kept markets jittery. Oura and some existing investors plan to raise up to $2.2 billion by selling 50 million shares at $40 to $44 each. Weight-loss drugmaker Eli Lilly has indicated interest in buying up to $100 million of the shares, and investment firm Dragoneer has indicated interest in up to $300 million. Oura's revenue surged roughly 74% year-over-year to $1.21 billion in the nine months ended June 30. The company reached a valuation of about $11 billion in a late-stage funding round last year. Samuel Kerr, global head of equity capital markets at Mergermarket, said Oura is the first real test of US appetite after a sluggish September, and a strong debut would encourage other issuers, while a weaker IPO might signal market sentiment is turning. Goldman Sachs, Morgan Stanley, and J.P. Morgan are the lead underwriters. Oura will list on the Nasdaq under the ticker symbol 'OURA'.
Read sourceOura targets $15.62 billion valuation in US IPO, testing investor appetite for fall listings
Oura, the smart ring maker, is targeting a fully diluted valuation of $15.62 billion in its US initial public offering, kicking off its roadshow on Monday. The deal tests investor appetite for consumer technology companies after a slow start to the fall IPO season, amid uncertainty around the AI trade, rising bond yields, and Federal Reserve rate hikes. Oura and some existing investors plan to raise up to $2.2 billion by selling 50 million shares at the top of the indicated price range of $40 to $44. Samuel Kerr, global head of equity capital markets at Mergermarket, said Oura is the first real test of US appetite after a sluggish September and volatile markets, and a strong debut would encourage other issuers, while a weaker IPO might signal turning market sentiment. Weight-loss drugmaker Eli Lilly has indicated interest in purchasing up to $100 million of the shares, and investment firm Dragoneer has indicated interest in buying up to $300 million worth. Oura's revenue surged roughly 74% year-over-year to $1.21 billion in the nine months ended June 30. The company reached a valuation of about $11 billion in a late-stage funding round last year. Goldman Sachs, Morgan Stanley, and J.P. Morgan are the lead underwriters. Oura will list on the Nasdaq under the ticker symbol 'OURA'.